Ascend Wellness HoldingsAAWH +4.61%42 EBITDA Margin % is 18.57% as of Mar. 2026, which is 54% above its 10-year median of 12.05. GuruFocus rates AAWH with a GF Score™ of 42/100 and a GF Value™ of $0.64 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, Ascend Wellness Holdings ranks worse than 50.42% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ascend Wellness Holdings EBITDA Margin % Related Terms
Ascend Wellness Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ascend Wellness Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascend Wellness Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ascend Wellness Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ascend Wellness Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascend Wellness Holdings (AAWH) has a EBITDA Margin % of 18.57% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ascend Wellness Holdings and its competitors. This is 54% above median its historical median of 12.05. According to the industry distribution chart, Ascend Wellness Holdings ranks #480 out of 952 companies in the Drug Manufacturers industry, placing it in the top 50.4%.
Is Ascend Wellness Holdings' EBITDA Margin % too high?
Ascend Wellness Holdings' current EBITDA Margin % of 18.57% is 54% above median its 10-year median of 12.05. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Ascend Wellness Holdings' value of 18.57% is 48.9% above this industry median. Based on the distribution chart, Ascend Wellness Holdings ranks #480 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ascend Wellness Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascend Wellness Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ascend Wellness Holdings ranks #480 out of 952 companies for EBITDA Margin %. This places Ascend Wellness Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.47. Ascend Wellness Holdings' value of 18.57% is 48.9% above this benchmark. While the company's 10-year median is 12.05 vs. the industry median of 12.47, Ascend Wellness Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascend Wellness Holdings's current EBITDA Margin % of 18.57% is 48.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ascend Wellness Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascend Wellness Holdings's current EBITDA Margin % is 18.57%, which is 54% above median its own 10-year median of 12.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascend Wellness Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ascend Wellness Holdings (AAWH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.64, compared to a current price of $0.47 — trading 26.9% below its estimated fair value. The current EBITDA Margin % is 18.57%, which is 54% above median its 10-year median of 12.05 and 48.9% above the Drug Manufacturers industry median of 12.47. Ascend Wellness Holdings' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ascend Wellness Holdings (AAWH), the current EBITDA Margin % is 18.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascend Wellness Holdings (AAWH) Overvalued in 2026?
Based on GuruFocus' analysis, Ascend Wellness Holdings stock appears to be undervalued.
The current stock price of $0.47 is trading 26.9% below its estimated GF Value™ of $0.64.
GuruFocus considers Ascend Wellness Holdings to be Possible Value Trap.
Key valuation signals for AAWH:
EBITDA Margin %: 18.57% (54% above median its 10-year median of 12.05)
GF Value™: $0.64 vs. price of $0.47 (26.9% below fair value)
Industry Position: 48.9% above the Drug Manufacturers median (#480 of 952)
No single metric tells the full story. See the AAWH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascend Wellness Holdings Inc is a vertically integrated multi-state operator focused on adult-use or near-term adult-use cannabis states in limited licenses markets. The company's core business is the cultivation, manufacturing, and distribution of cannabis consumer packaged goods, which it sells through company-owned retail stores and third-party licensed cannabis retail stores. It generates maximum revenue from the retail product segment.
42GF Score
Get the complete analysis for AAWH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AAWH has been successfully added to your 
